Patients with HSD17B13 variants had significantly lower rates of HCC complications (A/A vs. variants; 39 [18.4%] vs. 18 [9.5%], p = 0.01) and hypertension (120 [56.6%] vs. 90 [47.4%], p = 0.06). The gene discussed is HSD17B13; the disease is hepatocellular carcinoma.